Product Highlight - MENQUADFI

• Indicated for individuals from the age of 12 months and older¹
• Demonstrates high seroprotection in wide range of age groups, including older adults, across all four serogroups (A, C, W and Y)^1-6
• Well-documented safety profile^1-2
• Can be co-administered with other routine immunisations¹
• Fully liquid formulation with no reconstitution required¹

References:
1. MenQuadfi [SG Summary of Product Characteristics]. Singapore: Sanofi-Aventis (Singapore) Pte. Ltd.
2. van der Vliet D, Vesikari T, Sandner B, et al. lmmunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid conjugate vaccine in meningococcal vaccine-naive and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study. Epidemiol Infect. 2021;149:e50.
3. Baccarini Cl, Simon MW, Brandon D, et al. Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine in healthy meningococcal-naive children 2-9 years of age: a phase III, randomized study. Pediatr Infect Dis J. 2020;39:955-960.
4. Chang L-J, Hedrick J, Christensen S, et al. A phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. Vaccine. 2020;38:3560-3569.
5. Dhingra MS, Peterson J, Hedrick J, et al. lmmunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: a phase III randomized study. Vaccine. 2020;38:5194-5201.
6. Esteves-Jaramillo A, Koehler T, Jeanfreau R, et al. lmmunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in ≥56-year-olds: a phase III randomized study. Vaccine. 2020; 38:4405-4411.